Protein Degradation Congress Asia | Kisaco Research

Protein Degradation Congress Asia

Progressing translation of protein degradation probes into safe, effective therapeutics.

Download Agenda
Hong Kong
6-7 November, 2019

Poster session now open for submissions. Present your poster at the congress. Submit your abstract before 21 September 2019.

“A lot of data on PROTAC research has been disclosed on this event. And also many leaders in PROTAC shared their experience and concerns about PROTAC development. Many start up companies also delivered their progress. We can discuss future PROTAC directions as well as difficulties with experts from both industry and the academic area, and learned a lot. ”

Yuqing Huang - CFO, Kintor

Why Attend

“Targeted protein degradation promises to be the greatest innovation in small molecule drug discovery in the new millennium.” - Manfred Koegl, Lab Head Oncology Research, Boehringer Ingelheim

Following the global response to the inaugural European Congress earlier in May, Protein Degradation Congress Asia will bring together pan-Asian stakeholders to discuss one of the hottest drug discovery platforms within the pharmaceutical industry. Delegates will learn from experts from across Asia alongside leading European and American researchers – all driving the development of the ubiquitin-proteasome and targeted protein degradation spaces. Connect with leading industry players within big pharma and biotech along with expert academics in the ubiquitin space.

Learning from the rapid advancements globally, this meeting will provide an educational forum to drive preclinical studies within Asia by discussing the following:

  • Fundamental proteasome biology
  • Approaches to novel E3 ligase recruiters
  • Insights into bioavailability PK/PD data
  • Proteomics techniques to make the ‘undruggable’ druggable

Previous Attendees Include

Talk to our speakers about...

1. How to find new E3 ligase ligands

2. How can proteomics be used to make the 'undruggable' druggable?

3. Structural-based design of PROTAC through crystallography techniques

4. Furthering our understanding of the ubiquitin and proteasome space

5. New synthetic molecular glue approaches from auxin scaffolds

6. How well do PROTACs work in clinical application - insights into the first human trial

7. Key medicinal chemical considerations for moving from a PROTAC/molecular glue probe to drug

8. Novel degrader approaches including SNIPERs and peptide based PROTACs

9. How to exploit protein homeostasis to identify new proteins for degradation

10. Partnering opportunities within Asia for progressing discovery and launching preclinical studies

Highlights from Europe 2019

Protein degradation Congress

Who Will Be There

Pharma

Heads of Chemical Biology, Medicinal Chemistry, Proteomics, Discovery Biology, Pharmacology, Computational Biology

Biotech

Founder, Chief Scientific Officer, CEO, Chief Technology Officer

Academic & Research Institutes

Professor - Cell Biology, Research Fellow - Chemoproteomics, Director - Biochemistry

Service Providers

Equipment Manufacturers (Analysis, HTS), CRO/ CMO, Reagents, Delivery/ Computational Providers

Speakers

 

Ying Luo

CEO
Cullgen

Ying Luo

CEO
Cullgen

Ying Luo

CEO
Cullgen
 

Michael Chen

Head of External Innovation Asia
Merck

Dr. Chen Chen (Michael) currently works as Head of External Innovation China and APAC for Merck KGaA. Michael leads collaborations with academic institutions and local pharmaceutical companies in China and APAC areas with alignment of Merck R&D focus and requirement. He encompasses scouting and evaluation of external opportunities including assets from discovery to clinical development stages, new drug target/biomarker findings, and novel discovery technologies, through open innovation, licensing, co-development, investment and other collaboration models.

Michael Chen

Head of External Innovation Asia
Merck

Michael Chen

Head of External Innovation Asia
Merck

Dr. Chen Chen (Michael) currently works as Head of External Innovation China and APAC for Merck KGaA. Michael leads collaborations with academic institutions and local pharmaceutical companies in China and APAC areas with alignment of Merck R&D focus and requirement. He encompasses scouting and evaluation of external opportunities including assets from discovery to clinical development stages, new drug target/biomarker findings, and novel discovery technologies, through open innovation, licensing, co-development, investment and other collaboration models. He also provides his duties within Merck global BD team for various internalization and externalization opportunities.

 

Michael received his bachelor’s degree in cell and molecular biology from University of Essex, a master degree in cancer immunotherapy from University of Nottingham and a PhD in Biochemistry from Imperial College London. Before joining Merck, he has been leading research projects at Spirogen Ltd./MedImmune, and involved in business development/investment activities at WuXi AppTec and ChemPartner.

 

 

陈博士担任默克雪兰诺医药研发外部创新中国/亚太区负责人。工作内容与默克研发战略需求一致,通过与卓越的学术研究中心,以及中国和亚太地区制药公司的合作,来推动新的业务机会。他通过开放创新、引进许可、合作开发、投资和其他合作方式探索评估业务机会,内容包括:研发或者临床开发阶段的项目、新药靶标发现、新兴生物药技术等等。他同时还负责默克商务拓展部门的相关工作,开展各种内外部合作业务。

陈博士先后获得埃塞克斯大学获得细胞和分子生物学学士学位、诺丁汉大学获得癌症免疫治疗硕士学位、伦敦帝国学院获得生物化学博士学位。在加入默克之前,他一直在生物技术公司Spirogen以及阿斯利康旗下全球生物制药分公司MedImmune领导研究项目,并参与和无锡药名康德和睿智化学业务开发及投资活动。

 

Ruo Xu

VP in Chemistry
Suzhou Kintor Pharmaceuticals

Ruo Xu

VP in Chemistry
Suzhou Kintor Pharmaceuticals

Ruo Xu

VP in Chemistry
Suzhou Kintor Pharmaceuticals
 

Yu Rao

Associate Professor, The Department of Pharmaceutical Chemistry and Engineering, School of Pharmaceutical Science
Tsinghua University

Yu Rao

Associate Professor, The Department of Pharmaceutical Chemistry and Engineering, School of Pharmaceutical Science
Tsinghua University

Yu Rao

Associate Professor, The Department of Pharmaceutical Chemistry and Engineering, School of Pharmaceutical Science
Tsinghua University
 

Zigang Li

Principle Investigator
Peking University

Zigang Li

Principle Investigator
Peking University

Zigang Li

Principle Investigator
Peking University
 

Jianping Jin

Professor, Senior Investigator
Zhejiang University

Jianping Jin

Professor, Senior Investigator
Zhejiang University

Jianping Jin

Professor, Senior Investigator
Zhejiang University
 

Jing Liu

Executive Director of Chemistry
Cullgen

Jing Liu

Executive Director of Chemistry
Cullgen

Jing Liu

Executive Director of Chemistry
Cullgen
 

Xiaobao Yang

Professor
Shanghai Tech University

Xiaobao Yang

Professor
Shanghai Tech University

Xiaobao Yang

Professor
Shanghai Tech University
 

Mikihiko Naito

Chief, Division of Molecular Target and Gene Therapy Products
National Institute of Health Sciences

I have been studying cancer chemotherapy, cell death and protein degradation for many years, and developed SNIPER technology for targeted protein degradation. A goal of my research is to develop a novel drug based on the SNIPER technology. I have been collaborating with many researchers, and currently trying to start a new research group to accelerate the drug development.

Mikihiko Naito

Chief, Division of Molecular Target and Gene Therapy Products
National Institute of Health Sciences

Mikihiko Naito

Chief, Division of Molecular Target and Gene Therapy Products
National Institute of Health Sciences

I have been studying cancer chemotherapy, cell death and protein degradation for many years, and developed SNIPER technology for targeted protein degradation. A goal of my research is to develop a novel drug based on the SNIPER technology. I have been collaborating with many researchers, and currently trying to start a new research group to accelerate the drug development.

I love to eat chocolate with a cup of hot delicious tea. However, this combination facilitates producing kidney stones, which sometimes gave me painful experiences. I wish I could have them everyday without any concerns on the kidney stones.

 

 

Paras Koushal

Drug Safety Physician
Accenture

Paras Koushal

Drug Safety Physician
Accenture

Paras Koushal

Drug Safety Physician
Accenture

POSTER SESSION

Looking to showcase your recent work to the protein degradation community?

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.

Poster abstract submission deadline is on 21 September 2019. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

If you have any questions please contact [email protected] 

SUBMIT A POSTER ABSTRACT

What attendees say

Previous Sponsors

Previous Media Partners

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at partner@kisacoresearch.com.

The Agenda

Please download the agenda to find out more information about the congress including the main topics of discussion for the two days and our full lineup of speakers.

What you can expect from the Asia 2019 congress:

  • 150+ participants from leading industry players within big pharma and biotech along with expert academics in the ubiquitin

    space.

  • An open forum to share the latest in vivo and in vitro data and insights and foster collaboration. 
  • 10+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
  • 2 days of progressing translation of protein degradation probes into safe, effective therapeutics.

Download Agenda

Venue

Hong Kong

Venue to be confirmed. 

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Worldpay:
Wednesday, July 24, 2019 to Friday, September 6, 2019
Super Early Bird - Service Providers & Investors
$1,899
Super Early Bird ends 6th September 2019. Save $400
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Wednesday, July 24, 2019 to Friday, September 6, 2019
Super Early Bird - Biotech + Pharma
$899
Super Early Bird ends 6th September 2019. Save $500
Must have an active drug pipeline
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Wednesday, July 24, 2019 to Friday, September 6, 2019
Super Early Bird - Academic
$349
Super Early Bird ends 6th September 2019. Save $349
Must be a full time academic or healthcare professional
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.